Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1954 1
1955 1
1958 1
1959 2
1960 1
1962 1
1963 2
1964 1
1965 1
1966 1
1968 2
1969 1
1970 1
1972 2
2008 3
2009 1
2010 3
2011 2
2012 5
2013 8
2014 6
2015 14
2016 8
2017 3
2018 1
2019 3
2020 1
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
[Management of uveal melanomas, guidelines for oncologists].
Mathis T, Cassoux N, Tardy M, Piperno S, Gastaud L, Dendale R, Maschi C, Nguyen AM, Meyer L, Bonnin N, Baillif S, Tick S, Mouriaux F, Jaspart F, Dellis J, Rosier L, Desjardins L, Herault J, Caujolle JP, Thariat J. Mathis T, et al. Among authors: bonnin n. Bull Cancer. 2018 Oct;105(10):967-980. doi: 10.1016/j.bulcan.2018.07.011. Epub 2018 Sep 11. Bull Cancer. 2018. PMID: 30217336 Review. French.
Replacement of urethra.
BONNIN NJ. BONNIN NJ. Br J Urol. 1954 Jun;26(2):174-82. doi: 10.1111/j.1464-410x.1954.tb06083.x. Br J Urol. 1954. PMID: 13172464 No abstract available.
PRELP secreted from mural cells protects the function of blood brain barrier through regulation of endothelial cell-cell integrity.
Davaapil H, Hopkins J, Bonnin N, Papadaki V, Leung A, Kosuge H, Tashima T, Nakakido M, Sekido R, Tsumoto K, Sagoo MS, Ohnuma SI. Davaapil H, et al. Among authors: bonnin n. Front Cell Dev Biol. 2023 Oct 23;11:1147625. doi: 10.3389/fcell.2023.1147625. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37936982 Free PMC article.
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: bonnin n. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A. Reda M, et al. Among authors: bonnin n. Cancer Chemother Pharmacol. 2022 Feb;89(2):197-208. doi: 10.1007/s00280-021-04395-y. Epub 2022 Jan 8. Cancer Chemother Pharmacol. 2022. PMID: 34997290
Barriers to chimpanzee gene flow at the south-east edge of their distribution.
Bonnin N, Piel AK, Brown RP, Li Y, Connell AJ, Avitto AN, Boubli JP, Chitayat A, Giles J, Gundlapally MS, Lipende I, Lonsdorf EV, Mjungu D, Mwacha D, Pintea L, Pusey AE, Raphael J, Wich SA, Wilson ML, Wroblewski EE, Hahn BH, Stewart FA. Bonnin N, et al. Mol Ecol. 2023 Jul;32(14):3842-3858. doi: 10.1111/mec.16986. Epub 2023 Jun 5. Mol Ecol. 2023. PMID: 37277946
81 results